PANACEABIO
Panacea Biotec Limited (PANACEABIO) Stock Analysis
Panacea Biotec Limited develops vaccines, biosimilars, and pharmaceutical formulations for India and export markets. It has manufacturing facilities for sterile and oral dosage forms. The company is known for vaccine partnerships and public health supply. It is listed on Indian stock exchanges as a biopharma player.
Healthcare › Biotechnology
₹345.20
-3.84% 1W | -17.90% 52W
Market Cap
2.1k CR
P/E Ratio
–
52W High
₹647
52W Low
₹292.4
Div. Yield
0%
Beta
0.3
50 DMA
₹392
200 DMA
₹402.6
Profit Margin
-1.1%
Inst. Own.
0.2%
📊 CONSOLIDATION
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 | 141.13 | 165.19 | 166.75 | 199.57 |
| Expenses | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 | 158.92 | 153.45 | 164.18 | 193.90 |
| Operating Profit | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 | -17.79 | 11.74 | 2.57 | 5.67 |
| OPM % | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% | -12.61% | 7.11% | 1.54% | 2.84% |
| Other Income | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 | 9.10 | 5.05 | 5.26 | 6.98 |
| Interest | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 | 2.14 | 1.85 | 1.20 | 1.18 |
| Depreciation | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 | 8.34 | 8.45 | 7.88 | 7.90 |
| Profit before tax | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 | 3.57 |
| Tax % | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% | -26.92% | 40.06% | -20.00% | 38.38% |
| Net Profit | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1.00 | 2.20 |
| EPS in Rs | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 | 0.38 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 640 | 673 |
| Expenses | 643 | 541 | 505 | 509 | 591 | 484 | 548 | 674 | 558 | 579 | 584 | 644 | 670 |
| Operating Profit | 44 | 112 | 39 | 84 | -134 | 60 | 77 | -13 | -98 | -20 | -25 | -5 | 2 |
| OPM % | 6% | 17% | 7% | 14% | -29% | 11% | 12% | -2.0% | -21% | -3.5% | -4.4% | -0.7% | 0.3% |
| Other Income | 28 | 70 | 62 | 8 | 338 | -21 | 9 | 1,687 | 154 | 62 | 55 | 36 | 26 |
| Interest | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 6 | 6 |
| Depreciation | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 33 | 33 |
| Profit before tax | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 | -7 | -10 |
| Tax % | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% | -3% | |
| Net Profit | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | -7 | -9 |
| EPS in Rs | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | -0.88 | -1.16 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 12.0% | 0.0% | 0.0% |
| Profit CAGR | 21.0% | 13.0% | 5.0% |
Shareholding Pattern
Promoters72.48%
FIIs0.79%
DIIs1.52%
Public25.20%
Promoters72.48%
FIIs1.06%
DIIs1.80%
Public24.65%
Promoters72.48%
FIIs1.36%
DIIs1.85%
Public24.31%
Promoters72.48%
FIIs1.60%
DIIs1.96%
Public23.96%
Promoters72.48%
FIIs2.31%
DIIs2.25%
Public22.96%
Promoters73.59%
FIIs0.18%
DIIs0.43%
Public25.80%
Promoters73.59%
FIIs0.27%
DIIs0.84%
Public25.30%
Promoters72.48%
FIIs1.16%
DIIs1.49%
Public24.86%
Promoters72.48%
FIIs1.60%
DIIs1.96%
Public23.96%
Promoters72.48%
FIIs2.31%
DIIs2.25%
Public22.96%
PANACEABIO
Holdings Analysis
Key strengths & risk signals
49
Overall
50
Fundamental
49
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
WEAK POSITION! Current price (345.2) is below both moving averages.
WEAK YEAR! Stock declined 17.9% in the last year.
WEAK! Trading at 14.9% of 52W range - near yearly lows.
Strengths (4)
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
TESTING SUPPORT! Stock is at key support level.
APPROACHING OVERSOLD! RSI at 34.7 - watch for reversal.
Fundamental & Technical Analysis
49Overall
50Fundamental
49Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 10.1% (GOOD, 11/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -1.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 25.66% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
3/10
BEARISH TREND! 50-day average (392.0) is below 200-day average (402.6) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (345.2) is below both moving averages.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
2/10
WEAK YEAR! Stock declined 17.9% in the last year.
Volume Sentiment
15/30
BEARISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 91,690 vs down days: 93,914. Ratio: 0.98x
RSI
4/5
APPROACHING OVERSOLD! RSI at 34.7 - watch for reversal.
52W Range
1/5
WEAK! Trading at 14.9% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 3.8% (1 week), 12.3% (1 month), 36.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PANACEABIO | ₹345.20 | – | -1.1% | 10.1% | – | -17.9% | 49 | BOUNCE FROM SUPPORT | -42.5% | +360.0% | +19.7% | +19.7% |
| DCAL | ₹149.70 | 145.3 | 0.6% | 9.0% | 21.0% | -50.1% | 55 | BOUNCE FROM SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| HALEOSLABS | ₹1,563.70 | 29.9 | 4.9% | 0.3% | 14.7% | +41.6% | 69 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
| LYKALABS | ₹72.70 | – | -6.6% | 13.3% | – | -21.3% | 50 | BREAKDOWN | +133.3% | -127.6% | +28.2% | +51.1% |
| ZOTA | ₹1,324.10 | – | -17.0% | 56.7% | – | -7.9% | 57 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| 3BBLACKBIO | ₹1,586.40 | 24.1 | 36.3% | 31.9% | 32.2% | +40.7% | 76 | CONSOLIDATING UP | -24.6% | -1.0% | +50.9% | -5.4% |
| SUPRIYA | ₹847.60 | 34.4 | 22.7% | 21.2% | 32.5% | +23.4% | 83 | BOUNCE FROM SUPPORT | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹514.60 | 38 | 26.5% | 9.4% | 15.7% | -17.2% | 73 | BOUNCE FROM SUPPORT | -14.1% | +21.8% | -17.4% | +24.9% |
Data from TradeAlone · Updated daily
